| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(a month from now) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(7 months from now) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(7 months from now) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(7 months from now) | |
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
| US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(4 years from now) | |
Remodulin is owned by United Therap.
Remodulin contains Treprostinil.
Remodulin has a total of 13 drug patents out of which 2 drug patents have expired.
Expired drug patents of Remodulin are:
- US5153222
- US6765117
Remodulin was authorised for market use on 28 September, 2023.
Remodulin is available in solution;intravenous, subcutaneous, injectable;iv (infusion), subcutaneous dosage forms.
Remodulin can be used as administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration, treatment of pulmonary hypertension with ut-15, a method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer, a method of treating a human patient suffering from pulmonary hypertension, administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration.
The generics of Remodulin are possible to be released after 29 March, 2029.
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Treatment of pulmonary hypertension with ut-15; Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration...
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS; SOLUTION;INTRAVENOUS, SUBCUTANEOUS
REMODULIN family patents
